These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

547 related articles for article (PubMed ID: 24378007)

  • 1. Secondary cytoreductive surgery for isolated lymph node recurrence of epithelial ovarian cancer: a multicenter study.
    Ferrero A; Ditto A; Giorda G; Gadducci A; Greggi S; Daniele A; Fuso L; Panuccio E; Scaffa C; Raspagliesi F; Sismondi P; Biglia N
    Eur J Surg Oncol; 2014 Jul; 40(7):891-8. PubMed ID: 24378007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secondary cytoreductive surgery in patients presenting with isolated nodal recurrence of epithelial ovarian cancer.
    Fotiou S; Aliki T; Petros Z; Ioanna S; Konstantinos V; Vasiliki M; George C
    Gynecol Oncol; 2009 Aug; 114(2):178-82. PubMed ID: 19450872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes and patterns of secondary relapse in platinum-sensitive ovarian cancer: implications for tertiary cytoreductive surgery.
    Tang J; Liu DL; Shu S; Tian WJ; Liu Y; Zang RY
    Eur J Surg Oncol; 2013 Jul; 39(7):786-91. PubMed ID: 23490332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer.
    Santillan A; Karam AK; Li AJ; Giuntoli R; Gardner GJ; Cass I; Karlan BY; Bristow RE
    Gynecol Oncol; 2007 Mar; 104(3):686-90. PubMed ID: 17141302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
    Tu H; Huang H; Huang QD; Li Z; Feng YL; Liu JH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):928-33. PubMed ID: 23324194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical outcome of epithelial ovarian cancer patients with apparently isolated lymph node recurrence: a multicenter retrospective Italian study.
    Gadducci A; Cosio S; Zola P; Sostegni B; Ferrero AM; Teti G; Cristofani R; Sartori E
    Gynecol Oncol; 2010 Mar; 116(3):358-63. PubMed ID: 19954826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salvage lymphadenectomy in recurrent ovarian cancer patients: Analysis of clinical outcome and BRCA1/2 gene mutational status.
    Gallotta V; Bruno M; Conte C; Giudice MT; Davià F; Moro F; Zannoni GF; Fagotti A; De Bonis M; Capoluongo E; Scambia G; Ferrandina G
    Eur J Surg Oncol; 2020 Jul; 46(7):1327-1333. PubMed ID: 32085925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors for and prognostic value of mesenteric lymph node involvement in advanced-stage ovarian cancer.
    Gouy S; Goetgheluck J; Uzan C; Duclos J; Duvillard P; Morice P
    Eur J Surg Oncol; 2012 Feb; 38(2):170-5. PubMed ID: 22104389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer: a multi-institutional study.
    Deraco M; Virzì S; Iusco DR; Puccio F; Macrì A; Famulari C; Solazzo M; Bonomi S; Grassi A; Baratti D; Kusamura S
    BJOG; 2012 Jun; 119(7):800-9. PubMed ID: 22571746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for persistent and recurrent advanced ovarian carcinoma: a multicenter, prospective study of 246 patients.
    Bakrin N; Cotte E; Golfier F; Gilly FN; Freyer G; Helm W; Glehen O; Bereder JM
    Ann Surg Oncol; 2012 Dec; 19(13):4052-8. PubMed ID: 22825772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isolated lymph node relapse of epithelial ovarian carcinoma: outcomes and prognostic factors.
    Blanchard P; Plantade A; Pagès C; Afchain P; Louvet C; Tournigand C; de Gramont A
    Gynecol Oncol; 2007 Jan; 104(1):41-5. PubMed ID: 16952391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of systematic lymph node dissection in advanced epithelial ovarian cancer during interval debulking surgery performed after neoadjuvant chemotherapy.
    Eoh KJ; Yoon JW; Lee I; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
    J Surg Oncol; 2017 Sep; 116(3):329-336. PubMed ID: 28542980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiophrenic lymph node resection in cytoreduction for primary advanced or recurrent epithelial ovarian carcinoma: a cohort study.
    Lopes A; Rangel Costa RL; di Paula R; Anton C; Calheiros Y; Sartorelli V; Kanashiro YM; de Lima JA; Yamada A; Pinto GLS; Vianna MR; Nogueira Dias Genta ML; Ribeiro U; Dos Santos MO
    Int J Gynecol Cancer; 2019 Jan; 29(1):188-194. PubMed ID: 30640703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ovarian cancer patients with localized relapse: clinical outcome and prognostic factors.
    Petrillo M; Fagotti A; Ferrandina G; Fanfani F; Costantini B; Vizzielli G; Pedone Anchora L; Nero C; Margariti PA; Scambia G
    Gynecol Oncol; 2013 Oct; 131(1):36-41. PubMed ID: 23791829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minimally invasive secondary cytoreduction plus HIPEC for recurrent ovarian cancer: a case series.
    Fagotti A; Petrillo M; Costantini B; Fanfani F; Gallotta V; Chiantera V; Turco LC; Bottoni C; Scambia G
    Gynecol Oncol; 2014 Feb; 132(2):303-6. PubMed ID: 24378877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of cytoreductive surgery on survival of patients with recurrent epithelial ovarian cancer.
    Zang RY; Zhang ZY; Li ZT; Chen J; Tang MQ; Liu Q; Cai SM
    J Surg Oncol; 2000 Sep; 75(1):24-30. PubMed ID: 11025458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraperitoneal chemotherapy for recurrent epithelial ovarian cancer is feasible with high completion rates, low complications, and acceptable patient outcomes.
    Skaznik-Wikiel ME; Lesnock JL; McBee WC; Beriwal S; Zorn KK; Richard SD; Krivak TC; Edwards RP
    Int J Gynecol Cancer; 2012 Feb; 22(2):232-7. PubMed ID: 22080886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isolated lymph node recurrence in epithelial ovarian cancer - management and outcome.
    Jain V; Debnath S; Sharma A; Kamboj M; Mohanty A; Rawal S
    J Visc Surg; 2023 Jun; 160(3):169-179. PubMed ID: 36564260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subtypes of stage IV ovarian cancer; response to treatment and patterns of disease recurrence.
    Jamieson A; Sykes P; Eva L; Bergzoll C; Simcock B
    Gynecol Oncol; 2017 Aug; 146(2):273-278. PubMed ID: 28549816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interval between secondary cytoreductive surgery and adjuvant chemotherapy is not associated with survivals in patients with recurrent ovarian cancer.
    Jeong SY; Choi CH; Kim TJ; Lee JW; Kim BG; Bae DS; Lee YY
    J Ovarian Res; 2019 Dec; 13(1):1. PubMed ID: 31892329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.